Generic Semaglutide in South Africa: What Patients Should Know

Updated September 2026

Semaglutide has become one of the most widely discussed medicines in recent years. Until recently, South African patients had relatively few registered semaglutide products to choose from. That is beginning to change.

Generic semaglutide has now entered the South African market, and several additional products are being considered by the South African Health Products Regulatory Authority (SAHPRA).

What is semaglutide?

Semaglutide belongs to a group of medicines known as GLP-1 receptor agonists.

It works by mimicking the action of a naturally occurring hormone called GLP-1. This hormone plays a role in blood sugar regulation, digestion and appetite.

Semaglutide has been used internationally for several years and is the active ingredient found in well known medicines such as Ozempic and Wegovy.

Is generic semaglutide available in South Africa?

Yes.

In July 2026, Sun Pharmaceutical Industries became the first company to receive SAHPRA approval for a generic semaglutide injection in South Africa, Semagard.

This marked an important change in the local semaglutide market, which had previously been dominated by the original manufacturer.

The Sun Pharma product was approved in South Africa for the treatment of adults with type 2 diabetes whose blood sugar is not adequately controlled, together with appropriate diet and physical activity.

Patients should remember that registration applies to a particular medicine and its approved indication. It does not mean that every product advertised online as “generic semaglutide” has been approved by SAHPRA.

More generic semaglutide options are expected in South Africa

The South African semaglutide market is likely to become considerably more competitive.

On 21 July 2026, SAHPRA confirmed that it was reviewing 12 applications for generic semaglutide products following the expiry of the relevant semaglutide patent in South Africa.

This means South Africans are likely to see more registered generic semaglutide options becoming available in the future.

Not every application will necessarily receive approval, and regulatory review can take time. Each manufacturer still needs to satisfy SAHPRA regarding matters such as quality, manufacturing standards and the evidence supporting its product.

However, the number of applications suggests that several pharmaceutical companies are preparing to compete in the South African semaglutide market.

Greater competition could potentially improve availability and place downward pressure on prices over time, although the eventual retail price of each product will depend on the manufacturer, pharmacy pricing and other factors.

There are also other lower cost semaglutide options entering the market that are not technically generic medicines.

Novo Nordisk, together with Acino, announced an authorised semaglutide product called Extensior for South Africa in July 2026. It contains semaglutide and is manufactured using the same process and delivery device as Ozempic, but is sold under a different name.

An authorised copy (clone) and a generic medicine are not exactly the same regulatory category, but both developments mean that South Africans are beginning to have more registered semaglutide choices.

What does generic semaglutide actually mean?

A generic medicine contains the same active ingredient as the reference medicine and must meet the regulatory standards required for approval.

Generic medicines are commonly introduced after patent protection for an original medicine ends.

The manufacturer does not need to repeat every clinical trial performed during the development of the original medicine. Instead, it needs to provide the evidence required by regulators to demonstrate that its medicine meets the applicable standards.

Generic medicines are therefore often less expensive than the original brand, although the actual price difference can vary considerably.

Importantly, a lower price does not automatically mean a medicine is weaker or of lower quality.

A registered generic medicine has undergone regulatory assessment before being approved for sale.

Generic semaglutide and compounded semaglutide are not the same thing

This is one of the most important distinctions for patients to understand.

A registered generic semaglutide medicine has been reviewed and approved by SAHPRA.

A compounded semaglutide preparation is prepared for an individual patient under particular circumstances and does not go through the same product registration process.

SAHPRA states that compounded medicines are not reviewed by the regulator for safety, quality and effectiveness in the same way as registered medicines. A compounded preparation should not be described as a registered generic simply because it contains, or claims to contain, semaglutide.

What about semaglutide sodium and semaglutide acetate?

Patients should also be cautious about products containing substances described as semaglutide sodium or semaglutide acetate.

SAHPRA has specifically warned that these salt forms are not the same active ingredient used in registered semaglutide products.

According to SAHPRA, using semaglutide sodium, semaglutide acetate or another form of semaglutide other than the form contained in the registered medicine is not permissible for compounded medicines under the relevant provisions of the Medicines Act.

Patients should therefore ask exactly what product they are receiving rather than relying on the word “semaglutide” alone.

Why has there been concern about unregistered semaglutide?

The rapid increase in demand for GLP-1 medicines created an international market for compounded, imported and sometimes completely unregistered products.

South Africa has not been immune to this.

In May 2026, SAHPRA and the South African Pharmacy Council announced enforcement action following an investigation into the unlawful manufacturing and distribution of unregistered GLP-1 and GIP medicines.

The regulators reported significant concerns regarding manufacturing practices and seized injectable products found during the investigation.

This is why patients should distinguish between legitimate registered generic medicines and products simply being marketed as cheaper alternatives.

How can you check whether semaglutide is registered?

If you are offered a semaglutide product that you do not recognise, ask for its:

• Product name
• Manufacturer
• Strength
• SAHPRA registration details
• Patient information leaflet

Your pharmacist should also be able to confirm whether the medicine is registered.

Patients should obtain semaglutide through a licensed pharmacy or authorised dispenser and with an appropriate prescription.

SAHPRA warns that medicines obtained outside the legitimate supply chain may contain the wrong amount of active ingredient, another active ingredient entirely, harmful ingredients or microbial contamination.

Be particularly cautious of semaglutide being sold through informal social media accounts, messaging groups or websites that do not clearly identify the pharmacy supplying the medicine.

Will generic semaglutide be cheaper?

This is one of the main reasons generic semaglutide is attracting attention.

Generic competition usually gives pharmacies, doctors and patients more options and can reduce the cost of treatment.

However, there is no single “generic semaglutide price”.

Different manufacturers will set different prices and pharmacies may charge different dispensing fees. Prices may also vary according to dose and pack size.

For patients who use semaglutide continuously, even a relatively modest monthly price difference can become significant over the course of a year.

It is therefore worth comparing the cost of a complete prescribed supply rather than simply comparing the advertised price of individual pens.

Can you switch from one semaglutide product to another?

A switch should ideally be discussed with the prescribing doctor and dispensing pharmacist.

Although two products may contain semaglutide, their injection devices, concentrations and instructions may differ.

Patients should confirm the dose in milligrams and understand exactly how the new device is used before administering it.

Do not assume that a certain number of pen clicks, syringe markings or so called units from one product corresponds to the same dose from another product.

This is particularly important when moving between registered injection pens and compounded preparations where concentrations may differ.

Does generic semaglutide have side effects?

A generic medicine still contains semaglutide, so the known adverse effects associated with semaglutide remain relevant.

Common side effects can include:

• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort
• Reduced appetite

Some gastrointestinal symptoms improve as the body becomes accustomed to treatment, particularly when the dose is increased gradually.

More serious complications can occasionally occur, including pancreatitis, gallbladder problems and dehydration related kidney problems.

Persistent or severe abdominal pain, repeated vomiting or an inability to keep fluids down should not simply be ignored as an expected part of treatment.

What happens next for semaglutide in South Africa?

Patients should still focus on the exact product they are being prescribed rather than simply looking for the cheapest medicine advertised as semaglutide.

The most important distinction is becoming increasingly simple: registered generic semaglutide and unregistered products claiming to contain semaglutide are not the same thing.

As the market expands, checking that a medicine is registered, appropriately prescribed and supplied through a legitimate pharmacy will remain important.

This article is intended for general educational purposes and does not replace medical advice. Medicine registration, availability and pricing can change. Patients should confirm current product information with their doctor, pharmacist or SAHPRA.